Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.

Abstract: Provided is a long-acting PCSK9-specific binding protein and application thereof. Provided is an MV072 protein with unique complementarity-determining regions, i.e., a binding protein specifically binding to proprotein convertase subtilisin kexin type 9 (PCSK9). The protein can specifically bind to PCSK9, effectively inhibit the function of PCSK9 and reduce plasma LDL cholesterol level. Further provided is an application of the binding protein in treating diseases related to or influenced by the function of PCSK9.

Abstract: The invention features polypeptides that include an extracellular ActRIIa variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIa variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, e.g., Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, inclusion body myositis, amyotrophic lateral sclerosis, sarcopenia; or cancer cachexia; or metabolic diseases, e.g., obesity, Type-1 diabetes, or Type-2 diabetes.

Abstract: An object of the present invention is to provide an antibody against VEGF that inhibits binding of a vascular endothelial growth factor (VEGF) to neuropilin-1 (NRP1). The present invention provides an antibody against VEGF that inhibits binding of VEGF to NRP1.

Abstract: An object of the present invention is to provide an antibody having significantly high affinity for VEGF compared to the prior art. The present invention provides a monoclonal antibody against VEGF, which binds to a vascular endothelial growth factor (VEGF) with a dissociation constant of 1×10?11 mol/L or less.

Abstract: The present invention relates to a sustained type human growth hormone conjugate preparation comprising: a sustained type human growth hormone (hGH) conjugate resulting from conjugation between the immunoglobulin Fc region and a human growth hormone (hGH) constituting a bioactive peptide; a buffer solution; a nonionic surfactant; and a sugar alcohol. More specifically, the present invention relates to a sustained type human growth hormone conjugate freeze dried preparation and liquid preparation, to a production method for the freeze dried preparation, to a method of reconstituting the freeze dried preparation, and to a kit comprising the freeze dried preparation and a reconstituting solution.

Abstract: The human LIV21 protein as a diagnostic and prognostic marker for various cancers and neurodegenerative diseases is provided. Methods for diagnosing and/or prognosing cancer utilizing the LIV21 protein and various derivatives and peptide fragments of the LIV21 protein are also provided.

Abstract: The invention refers to medicine and pharmacology, namely, to biologically active peptides, which modulate purinergic signaling. For that, the peptide with the following amino acid sequence is proposed: Gly1-Tyr2-Cys3-Ala4-Thr5-Lys6-Gly7-Ile8-Lys9-Cys10- Asn11-Asp12-Ile13-His14-Cys15-Cys16-Ser17-Gly18-Leu19- Lys20-Cys21-Asp22-Ser23-Lys24-Arg25-Lys26-Val27-Cys28- Val29-Lys30-Gly31, or a sequence with at least 90% homology hereto. Peptides in the invention can be used for prevention and treatment of diseases mediated by purinergic receptors. The peptides can be used for development of new drugs on their basis, for example, analgesics, as well for investigation of mechanisms of pain occurrence, for identification and testing of new modulators of P2X3 receptors. The peptides in the invention can be produced using chemical synthesis or biotechnologically using the nucleotide sequence of the corresponding gene.

Abstract: In certain aspects, the present invention provides compositions and methods for inducing utrophin expression in muscle with an ActRIIB protein as therapy for muscular dystrophy. The present invention also provides methods of screening compounds that modulate activity of an ActRIIB protein and/or an ActRIIB ligand.

Abstract: Disclosed is a medicine containing a long-lasting human growth hormone preparation as an active ingredient, which has low prolactin-like activity and shows long half-life in blood as compared with 22K human growth hormone. The long-lasting human growth hormone includes a fusion protein exhibiting growth-promoting activity and having a human serum albumin part and a 20K human growth hormone part, particularly a fusion protein in which the 20K human growth hormone part is linked to C-terminus of the human serum albumin part via a linker sequence.

Abstract: The present invention relates to a novel protein formulation. In particular, the invention relates to a liquid pharmaceutical composition of an antibody directed to Interleukin-6 receptor, a method of manufacturing the composition, a kit including the composition, a package including the composition and to methods of treatment using the composition and/or package.

Abstract: Monoclonal antibodies and antibody fragments that specifically bind to matrilin-3, conjugates including these molecules, and nucleic acid molecules encoding the antibodies, antigen binding fragments and conjugates, are disclosed. Also disclosed are compositions including the disclosed antibodies, antigen binding fragments, conjugates, and nucleic acid molecules. Methods of treating or inhibiting a cartilage disorder in a subject, as well as methods of increasing chondrogenesis in cartilage tissue are further provided. The methods can be used, for example, for treating or inhibiting a growth plate disorder in a subject, such as a skeletal dysplasia or short stature.

Abstract: The present invention provides antibodies and antigen binding fragments thereof that bind to human Follistatin-Like-3 (FSTL3) protein, compositions comprising such antibodies, and methods of making and using such antibodies.

Abstract: The present invention relates to antibodies having activity against a vascular endothelial growth factor (VEGF), and methods of making and using such antibodies.

Abstract: Disclosed herein is a method for identifying TREM-1's ligand and antibodies, or fragments thereof, which are capable of modifying the function of TREM-1's ligand. Antibodies that reduce or block TREM-1 activation may be identified and selected using this method. Antibodies that bind to TREM-1's ligand and reduce TREM-1 activity may be suitable for use as medicaments.

Abstract: Methods of treating acute thyroid eye disease (TED) by administering a inhibitor, e.g., a VEGF-A inhibitor, e.g., an anti-VEGF antibody, optionally in combination with hyaluronidase, by periorbital or intraorbital injection. Also compositions comprising a VEGF inhibitor and hyaluronidase.

Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.

Abstract: The present disclosure relates to, among other things, compounds and methods for treating neuropathic pain, ocular pain, ocular inflammation, and/or dry eye and methods of detecting mutations in specific G-protein coupled receptors, such as missense mutations, and determining the extent to which these mutations alter the pharmacological response of the G-protein coupled receptor.

Abstract: Antibody drug conjugates (ADC's) that bind to 191P4D12 protein and variants thereof are described herein. 191P4D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.

Abstract: The present invention provides the use of neuregulin protein for the preparation of medication for preventing, treating or delaying heart failure in humans and methods for preventing, treating or delaying heart failure in humans using said medication.